JSL reports consulting fees from AbbVie and honoraria from Janssen. PAO reports consulting fees from AbbVie, Takeda, and Janssen; honoraria from Takeda and Janssen; and financial support for attending meetings, travel, or both from AbbVie, Takeda, Janssen, and Ferring. LP-B reports grants from AbbVie, MSD, Takeda, and Fresenius Kabi; consulting fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; honoraria from AbbVie, Galapagos, Janssen, Ferring, Tillots, Celltrion, Takeda, Pfizer, Sandoz, Biogen, MSD, Arena, Gilead, Amgen, Vifor, and Viatris; financial support for attending meetings, travel, or both from AbbVie, Galapagos, Janssen, Ferring, Tillots, Celltrion, Takeda, Pfizer, Sandoz, Biogen, MSD, Arena, Gilead, Amgen, and Vifor; participation on a data safety monitoring board or advisory board for Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; and stock options from CTMA.